Retroperitoneal solitary fibrous tumor: surgery as first line therapy

Clinical Sarcoma Research

Kiran K. Turaga²  John Charlson¹  Meena Bedi³  Fabian M. Johnston²  Thejus T. Jayakrishnan²  Mohit Patel²  Rahul Rajeev² 

[1] Section of Hematology and Oncology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee 53226, WI, USA;Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee 53226, WI, USA;Department of Radiation Oncology, Medical College of Wisconsin, 8701 Watertown Plank Rd., Milwaukee 53226, WI, USA

关键词: Surgical Oncology;    Surgical outcomes;    Adjuvant radiotherapy;    Adjuvant chemotherapy;    Retroperitoneal sarcoma;    Solitary fibrous tumors;   

Others  :  1223054
DOI  :  10.1186/s13569-015-0034-y

 received in 2015-05-19, accepted in 2015-08-07,  发布年份 2015

【 摘 要 】

Background

Solitary fibrous tumors (SFT) of the retroperitoneum are rare spindle cell neoplasms, with a paucity of data on treatment outcomes. We hypothesized that surgical excision offered acceptable outcomes in SFTs.

Methods

The National Cancer Database (NCDB) was used to identify patients with SFT from 2004 to 2011. Primary outcome measures were 30 day mortality and overall survival. Descriptive analyses were performed. Furthermore, a systematic review of published literature was conducted after creating a pre-specified search strategy.

Results

Of 51 patients in the NCDB, 58.8 % (n = 30) were males, with a median age 60 years (IQR 49–72 years). Median tumor size was 16 cm (IQR 11–21 cm). Surgical resection was performed in 92.2 % (n = 47) with 63.8 % (n = 30) having a margin negative resection. Peri-operative mortality was 2.1 % (n = 1). Of survival outcomes available for 18 patients, the median OS was 51.1 months. From the systematic review, we identified 8 studies, with 24 patients. Median age and tumor size was similar to the NCDB [47.5 years (IQR 39–66.5 years), 12 cm (IQR 7–17 cm)]. Majority [91.7 % (n = 22)] underwent surgical excision alone while one received adjuvant chemotherapy and none received radiation. After median follow up of 54 months (IQR 28–144 months), 79.2 % (n = 19) were alive without disease. Three patients (12.5 %) died of disease, one was alive with disease and one was lost to follow up. Recurrence was reported in 16.7 % (n = 4) of patients.

Conclusion

Complete surgical excision is a viable treatment modality for retroperitoneal SFT leading to long term survival. Low recurrence rates would argue against the need for routine adjuvant radiation or chemotherapy.

【 授权许可】

   
2015 Rajeev et al.

【 图 表 】

Fig.1.

【 参考文献 】

• [1]Klemperer PRC. Primary neoplasms of the pleura. A report of five cases. Arch Pathol. 1931; 11:385-412.
• [2]Baldi GG, Stacchiotti S, Mauro V, Dei Tos AP, Gronchi A, Pastorino U et al.. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. Clin Sarcoma Res. 2013; 3:4. BioMed Central Full Text
• [3]Hasegawa T, Matsuno Y, Shimoda T, Hasegawa F, Sano T, Hirohashi S. Extrathoracic solitary fibrous tumors: their histological variability and potentially aggressive behavior. Hum Pathol. 1999; 30(12):1464-1473.
• [4]Briselli M, Mark EJ, Dickersin GR. Solitary fibrous tumors of the pleura: eight new cases and review of 360 cases in the literature. Cancer. 1981; 47(11):2678-2689.
• [5]England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989; 13(8):640-658.
• [6]Takizawa I, Saito T, Kitamura Y, Arai K, Kawaguchi M, Takahashi K et al.. Primary solitary fibrous tumor (SFT) in the retroperitoneum. Urol Oncol Semin Ori. 2008; 26(3):254-259.
• [7]Kanthan R, Torkian B. Recurrent solitary fibrous tumor of the pleura with malignant transformation. Arch Pathol Lab Med. 2004; 128(4):460-462.
• [8]Tominaga N, Kawarasaki C, Kanemoto K, Yokochi A, Sugino K, Hatanaka K et al.. Recurrent solitary fibrous tumor of the pleura with malignant transformation and non-islet cell tumor-induced hypoglycemia due to paraneoplastic overexpression and secretion of high-molecular-weight insulin-like growth factor II. Intern Med. 2012; 51(23):3267-3272.
• [9]Vallat-Decouvelaere AV, Dry SM, Fletcher CD. Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol. 1998; 22(12):1501-1511.
• [10]Gold JS, Antonescu CR, Hajdu C, Ferrone CR, Hussain M, Lewis JJ et al.. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002; 94(4):1057-1068.
• [11]Cranshaw IM, Gikas PD, Fisher C, Thway K, Thomas JM, Hayes AJ. Clinical outcomes of extra-thoracic solitary fibrous tumours. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2009; 35(9):994-998.
• [12]Yokoi T, Tsuzuki T, Yatabe Y, Suzuki M, Kurumaya H, Koshikawa T et al.. Solitary fibrous tumour: significance of p53 and CD34 immunoreactivity in its malignant transformation. Histopathology. 1998; 32(5):423-432.
• [13]Robinson LA. Solitary fibrous tumor of the pleura. Cancer Control J Moffitt Cancer Cent. 2006; 13(4):264-269.
• [14]de Perrot M, Kurt AM, Robert JH, Borisch B, Spiliopoulos A. Clinical behavior of solitary fibrous tumors of the pleura. Ann Thorac Surg. 1999; 67(5):1456-1459.
• [15]Lee SY, Goh BK, Teo MC, Chew MH, Chow PK, Wong WK et al.. Retroperitoneal liposarcomas: the experience of a tertiary Asian center. World J Surg Oncol. 2011; 9:12. BioMed Central Full Text
• [16]Lochan R, French JJ, Manas DM. Surgery for retroperitoneal soft tissue sarcomas: aggressive re-resection of recurrent disease is possible. Ann Roy Coll Surg. 2011; 93(1):39-43.
• [17]Mosquera JM, Fletcher CD. Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component—is this dedifferentiated SFT? Am J Surg Pathol. 2009; 33(9):1314-1321.
• [18]Demicco EG, Park MS, Araujo DM, Fox PS, Bassett RL, Pollock RE et al.. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol Off J US Can Acad Pathol Inc. 2012; 25(9):1298-1306.
• [19]van Houdt WJ, Westerveld CM, Vrijenhoek JE, van Gorp J, van Coevorden F, Verhoef C et al.. Prognosis of solitary fibrous tumors: a multicenter study. Ann Surg Oncol. 2013; 20(13):4090-4095.
• [20]Wilky BA, Montgomery EA, Guzzetta AA, Ahuja N, Meyer CF. Extrathoracic location and “borderline” histology are associated with recurrence of solitary fibrous tumors after surgical resection. Ann Surg Oncol. 2013; 20(13):4080-4089.
• [21]Wignall OJ, Moskovic EC, Thway K, Thomas JM. Solitary fibrous tumors of the soft tissues: review of the imaging and clinical features with histopathologic correlation. AJR Am J Roentgenol. 2010; 195(1):W55-W62.
• [22]Langman G. Solitary fibrous tumor: a pathological enigma and clinical dilemma. J Thorac Dis. 2011; 3(2):86-87.
• [23]Mohajeri A, Tayebwa J, Collin A, Nilsson J, Magnusson L, von Steyern FV et al.. Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosom Cancer. 2013; 52(10):873-886.
• [24]Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE et al.. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013; 125(5):651-658.
• [25]Robinson DR, Wu YM, Kalyana-Sundaram S, Cao X, Lonigro RJ, Sung YS et al.. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013; 45(2):180-185.
• [26]Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol Off J US Can Acad Pathol Inc. 2014; 27(3):390-395.
• [27]Law MK, Tung YW, Jinc JS. Malignant transformation in solitary fibrous tumor of the pleura. Asian Cardiovasc Thorac Ann. 2014; 22(8):981-983.
• [28]Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ et al.. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011; 117(21):4939-4947.
• [29]Lackner H, Urban C, Dornbusch HJ, Schwinger W, Kerbl R, Sovinz P. Interferon alfa-2a in recurrent metastatic hemangiopericytoma. Med Pediatr Oncol. 2003; 40(3):192-194.
• [30]Kirn DH, Kramer A. Long-term freedom from disease progression with interferon alfa therapy in two patients with malignant hemangiopericytoma. J Natl Cancer Inst. 1996; 88(11):764-765.
• [31]Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G et al.. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. Eur J Cancer. 2014; 50(17):3021-3028.
• [32]Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B et al.. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol Off J Eur Soc Med Oncol Esmo. 2012; 23(12):3171-3179.
• [33]Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A et al.. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res Off J Am Assoc Cancer Res. 2013; 19(18):5192-5201.
• [34]Park MS, Ravi V, Conley A, Patel SR, Trent JC, Lev DC et al.. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res. 2013; 3(1):7. BioMed Central Full Text
• [35]Clayton AC, Salomao DR, Keeney GL, Nascimento AG. Solitary fibrous tumor: a study of cytologic features of six cases diagnosed by fine-needle aspiration. Diagn Cytopathol. 2001; 25(3):172-176.
• [36]Morimitsu Y, Nakajima M, Hisaoka M, Hashimoto H. Extrapleural solitary fibrous tumor: clinicopathologic study of 17 cases and molecular analysis of the p53 pathway. APMIS Acta Pathol Microbiol Immunol Scand. 2000; 108(9):617-625.
• [37]Guillou L, Gebhard S, Coindre JM. Lipomatous hemangiopericytoma: a fat-containing variant of solitary fibrous tumor? Clinicopathologic, immunohistochemical, and ultrastructural analysis of a series in favor of a unifying concept. Hum Pathol. 2000; 31(9):1108-1115.